Your browser doesn't support javascript.
loading
NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma.
Adler, Amanda I; Slayen, Samuel; Stegenga, Heather; Guo, Yelan; Diaz, Richard; Welton, Nicky J; Westwood, Nigel; Doull, Iolo; Crawley, Charles.
Afiliação
  • Adler AI; Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LE, UK. Electronic address: amanda.adler@dtu.ox.ac.uk.
  • Slayen S; National Institute of Health and Care Excellence, Manchester and London, UK.
  • Stegenga H; National Institute of Health and Care Excellence, Manchester and London, UK.
  • Guo Y; National Institute of Health and Care Excellence, Manchester and London, UK.
  • Diaz R; National Institute of Health and Care Excellence, Manchester and London, UK.
  • Welton NJ; Bristol Medical School, University of Bristol, Bristol, UK.
  • Westwood N; Shrewton, Wiltshire, UK.
  • Doull I; Welsh Health Specialised Services Committee, Pontypridd, UK.
  • Crawley C; National Institute of Health and Care Excellence, Manchester and London, UK; Addenbrooke's Hospital, Cambridge, UK.
Lancet Respir Med ; 10(10): e92-e93, 2022 10.
Article em En | MEDLINE | ID: mdl-35988573
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pleurais / Mesotelioma Maligno / Mesotelioma Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pleurais / Mesotelioma Maligno / Mesotelioma Idioma: En Ano de publicação: 2022 Tipo de documento: Article